StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the stock. A number of other research firms have also recently commented on OCX. Benchmark restated a speculative buy rating and issued a $5.00 price objective on shares of OncoCyte […]